



THIEVON-WRIGHT

CONSULTING GROUP®

Thievon-Wright Consulting Group
12 New Providence Road, Watchung, NJ 07069
www.cnssites.com
Office: (908) 756-4411 • Fax: (908) 756-1122
Email: info@cnssites.com

Schizophrenia Case Study 2

A Phase 2, Multicenter, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Study to Evaluate the Safety and Efficacy of Two Fixed Doses of XXXXX Compared to Placebo in the Treatment of Acute Exacerbation of Schizophrenia Using Risperidone as an Active Control

Rick Mofsen, DO

Key Elements:

- Clintara review
- Long Confinement
- Inpatient

Indication: Schizophrenia (Acute)

of Subjects: 13 subjects screened; 5 subjects screen failed; 6 completed; 2 terminated early

In-patient Period: 28-35 Days

Objectives

Primary

- Efficacy using the PANSS to measure change in symptoms
- Safety and tolerability of two fixed dose regimens of XXXXX
- Incidence rate of dystonia

Secondary

- Safety: Adverse events, weight and abdominal girth, vital signs, physical examination, neurological examination, electrocardiogram (ECG) and clinical laboratory findings
- Change from baseline to Week 4 on:
 - PANSS
 - CGI-Severity
 - Brief Psychiatric Rating Scale (BPRS)
 - CGI-Improvement
 - Global Assessment of Functioning (GAF)
 - Treatment Satisfaction Questionnaire for Medication (TSQM)

Ratings

Brief Psychiatric Rating Scale (BPRS)
Positive and Negative Syndrome Scale (PANSS)
Clinical Global Impression-Severity (CGI-S)
Clinical Global Impression-Improvement (CGI-I)
Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A)
Global Assessment of Functioning (GAF)
Treatment Satisfaction Questionnaire for Medication (TSMQ)
Columbia-Suicide Severity Rating Scale (C-SSRS)
Suicidal Behavior Questionnaire Revised (SBQ-R)

Lab Assessments—43 per subject

Screening, Days 1-28, Follow-up

ECGs (Triplicate)

Screening, Day 1, Day 14, Day 28, Follow-up

Vitals

Screening, Days 1-29, Follow-up

Clintara

- Appropriate subject selection confirmed by Clintara through C-Visa (Clinical Validation Inventory for Subject Admission)
 - Diagnostic verification, symptom severity confirmation, subject validity and reliability
- All 13 subjects screened by St. Louis Clinical Trials passed independent review by Clintara without disagreement (i.e., no tier 2 review necessary)